Literature DB >> 24756197

Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Aziz Guellich1, Hind Mehel, Rodolphe Fischmeister.   

Abstract

Cyclic AMP regulates a multitude of cellular responses and orchestrates a network of intracellular events. In the heart, cAMP is the main second messenger of the β-adrenergic receptor (β-AR) pathway producing positive chronotropic, inotropic, and lusitropic effects during sympathetic stimulation. Whereas short-term stimulation of β-AR/cAMP is beneficial for the heart, chronic activation of this pathway triggers pathological cardiac remodeling, which may ultimately lead to heart failure (HF). Cyclic AMP is controlled by two families of enzymes with opposite actions: adenylyl cyclases, which control cAMP production and phosphodiesterases, which control its degradation. The large number of families and isoforms of these enzymes, their different localization within the cell, and their organization in macromolecular complexes leads to a high level of compartmentation, both in space and time, of cAMP signaling in cardiac myocytes. Here, we review the expression level, molecular characteristics, functional properties, and roles of the different adenylyl cyclase and phosphodiesterase families expressed in heart muscle and the changes that occur in cardiac hypertrophy and failure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24756197     DOI: 10.1007/s00424-014-1515-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  151 in total

1.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

2.  Effects of cardiac overexpression of type 6 adenylyl cyclase affects on the response to chronic pressure overload.

Authors:  Aziz Guellich; Shumin Gao; Chull Hong; Lin Yan; Thomas E Wagner; Sunil K Dhar; Bijan Ghaleh; Luc Hittinger; Kosaku Iwatsubo; Yoshihiro Ishikawa; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

3.  Adenylyl cyclase 6 deletion reduces left ventricular hypertrophy, dilation, dysfunction, and fibrosis in pressure-overloaded female mice.

Authors:  Tong Tang; N Chin Lai; H Kirk Hammond; David M Roth; Yuan Yang; Tracy Guo; Mei Hua Gao
Journal:  J Am Coll Cardiol       Date:  2010-04-06       Impact factor: 24.094

4.  Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a.

Authors:  C L Antos; N Frey; S O Marx; S Reiken; M Gaburjakova; J A Richardson; A R Marks; E N Olson
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

Review 5.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Authors:  Rodolphe Fischmeister; Liliana R V Castro; Aniella Abi-Gerges; Francesca Rochais; Jonas Jurevicius; Jérôme Leroy; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

6.  Altering the receptor-effector ratio by transgenic overexpression of type V adenylyl cyclase: enhanced basal catalytic activity and function without increased cardiomyocyte beta-adrenergic signalling.

Authors:  N M Tepe; J N Lorenz; A Yatani; R Dash; E G Kranias; G W Dorn; S B Liggett
Journal:  Biochemistry       Date:  1999-12-14       Impact factor: 3.162

7.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 8.  What is the role of beta-adrenergic signaling in heart failure?

Authors:  Martin J Lohse; Stefan Engelhardt; Thomas Eschenhagen
Journal:  Circ Res       Date:  2003-11-14       Impact factor: 17.367

9.  PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects.

Authors:  Enrico Patrucco; Antonella Notte; Laura Barberis; Giulio Selvetella; Angelo Maffei; Mara Brancaccio; Stefano Marengo; Giovanni Russo; Ornella Azzolino; Sergei D Rybalkin; Lorenzo Silengo; Fiorella Altruda; Reinhard Wetzker; Matthias P Wymann; Giuseppe Lembo; Emilio Hirsch
Journal:  Cell       Date:  2004-08-06       Impact factor: 41.582

10.  Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling.

Authors:  Peter T Wright; Viacheslav O Nikolaev; Thomas O'Hara; Ivan Diakonov; Anamika Bhargava; Sergiy Tokar; Sophie Schobesberger; Andrew I Shevchuk; Markus B Sikkel; Ross Wilkinson; Natalia A Trayanova; Alexander R Lyon; Sian E Harding; Julia Gorelik
Journal:  J Mol Cell Cardiol       Date:  2013-12-15       Impact factor: 5.000

View more
  24 in total

1.  UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.

Authors:  Li Wang; Brian T Burmeister; Keven R Johnson; George S Baillie; Andrei V Karginov; Randal A Skidgel; John P O'Bryan; Graeme K Carnegie
Journal:  Cell Signal       Date:  2015-02-12       Impact factor: 4.315

2.  A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.

Authors:  Si Chen; Yishuai Zhang; Janet K Lighthouse; Deanne M Mickelsen; Jiangbin Wu; Peng Yao; Eric M Small; Chen Yan
Journal:  Circulation       Date:  2019-12-05       Impact factor: 29.690

Review 3.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 4.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

5.  Cardiac adenylyl cyclase overexpression precipitates and aggravates age-related myocardial dysfunction.

Authors:  Nathalie Mougenot; Delphine Mika; Gabor Czibik; Elizabeth Marcos; Shariq Abid; Amal Houssaini; Benjamin Vallin; Aziz Guellich; Hind Mehel; Daigo Sawaki; Grégoire Vandecasteele; Rodolphe Fischmeister; Roger J Hajjar; Jean-Luc Dubois-Randé; Isabelle Limon; Serge Adnot; Geneviève Derumeaux; Larissa Lipskaia
Journal:  Cardiovasc Res       Date:  2019-10-01       Impact factor: 10.787

6.  Differences in the control of basal L-type Ca(2+) current by the cyclic AMP signaling cascade in frog, rat, and human cardiac myocytes.

Authors:  Rimantas Treinys; Andrius Bogdelis; Lina Rimkutė; Jonas Jurevičius; Vytenis Arvydas Skeberdis
Journal:  J Physiol Sci       Date:  2015-12-16       Impact factor: 2.781

7.  Electrostatic steering enhances the rate of cAMP binding to phosphodiesterase: Brownian dynamics modeling.

Authors:  Yu-ming M Huang; Gary Huber; J Andrew McCammon
Journal:  Protein Sci       Date:  2015-09-08       Impact factor: 6.725

Review 8.  Cardiac cAMP: production, hydrolysis, modulation and detection.

Authors:  Cédric Boularan; Céline Gales
Journal:  Front Pharmacol       Date:  2015-10-01       Impact factor: 5.810

Review 9.  An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.

Authors:  Si Chen; Chen Yan
Journal:  Expert Opin Drug Discov       Date:  2020-09-21       Impact factor: 6.098

Review 10.  Studying GPCR/cAMP pharmacology from the perspective of cellular structure.

Authors:  Peter T Wright; Sophie Schobesberger; Julia Gorelik
Journal:  Front Pharmacol       Date:  2015-07-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.